Regulatory role of nucleophosmin during the differentiation of human liver cancer cells

Xu,Dong-Hui; Liu,Fan; Li,Xiao; Chen,Xiang-Feng; Jing,Guang-Jun; Wu,Fu-Yun; Shi,Song-Lin; Li,Qi-Fu

doi:10.3892/ijo.2014.2407

Regulatory role of nucleophosmin during the differentiation of human liver cancer cells

Authors:
- Dong-Hui Xu
- Fan Liu
- Xiao Li
- Xiang-Feng Chen
- Guang-Jun Jing
- Fu-Yun Wu
- Song-Lin Shi
- Qi-Fu Li
View Affiliations

Affiliations: Department of Hepatic Biliary Pancreatic Vascular Surgery, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China, Medical College of Xiamen University, Xiamen, Fujian 361102, P.R. China , School of Life Sciences, Xiamen University, Xiamen, Fujian 361102, P.R. China
Published online on: April 29, 2014 https://doi.org/10.3892/ijo.2014.2407
Pages: 264-272

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleophosmin (NPM, also known as B23), mainly localized in the nucleolus, has been reported to be overexpressed in many types of human cancer, including colon, ovarian, prostate and gastric cancer. NPM was identified while screening the differential nuclear matrix proteins during HMBA-induced differentiation of human liver cancer cells. We investigated the aberrant expression and subcellular localization of NPM in clinical liver cancer tissues and a cell line with the aim of providing more evidence for revealing the roles of NPM on regulating liver cancer cell proliferation and differentiation. In addition, we studied the potential interaction between NPM and several important proteins. Our results revealed that NPM protein was overexpressed in cancer cells, which was in accordance with the overexpressed mRNA in cancer tissues compared to the corresponding non-cancer tissues. We also found a decrease of NPM in protein and mRNA levels upon treatment with the differentiation reagent HMBA. We focused on the aberrant localization of NPM. Immunochemistry and immunofluorescence revealed aberrant cytoplasmic and nucleoplasm localization of NPM in liver cancer tissues and its colocalization with c-Myc, c-Fos, P53 and Rb in the SMMC-7721 cell line. The interactions between NPM and the above proteins were confirmed by GST pull-down assay and co-immunoprecipitation assay. These findings indicate that NPM plays a regulatory role in liver cancer, which deserves in-depth investigation.

View Figures

View References

1.	Grisendi S, Mecucci C, Falini B and Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer. 6:493–505. 2006. View Article : Google Scholar
2.	Lindström MS: Elucidation of motifs in ribosomal protein S9 that mediate its nucleolar localization and binding to NPM1/nucleophosmin. PLoS One. 7:e524762012.PubMed/NCBI
3.	Lim MJ and Wang XW: Nucleophosmin and human cancer. Cancer Detect Prev. 30:481–490. 2006. View Article : Google Scholar
4.	Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL and Yung BY: Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin. 29:364–370. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Hsu CY and Yung BY: Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int J Cancer. 88:392–400. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Li QF, Shi SL, Liu QR, Tang J, Song J and Liang Y: Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin. Int J Biochem Cell Biol. 40:1918–1929. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Liang Y, Li QF, Zhang XY, Shi SL and Jing GJ: Differential expression of nuclear matrix proteins during the differentiation of human neuroblastoma SK-N-SH cells induced by retinoic acid. J Cell Biochem. 106:849–857. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Tang J, Niu JW, Xu DH, Li ZX, Li QF and Chen JA: Alteration of nuclear matrix-intermediate filament system and differential expression of nuclear matrix proteins during human hepato-carcinoma cell differentiation. World J Gastroenterol. 13:2791–2797. 2007.
9.	Derenzini M, Sirri V, Trere D and Ochs RL: The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest. 73:497–502. 1995.
10.	Michishita E, Kurahashi T, Suzuki T, et al: Changes in nuclear matrix proteins during the senescence-like phenomenon induced by 5-chlorodeoxyuridine in HeLa cells. Exp Gerontol. 37:885–890. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Hsu CY and Yung BY: Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. Oncogene. 16:915–923. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Dergunova NN, Bulycheva TI, Artemenko EG, et al: A major nucleolar protein B23 as a marker of proliferation activity of human peripheral lymphocytes. Immunol Lett. 83:67–72. 2002. View Article : Google Scholar
13.	Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK and Partin AW: Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate. 39:298–304. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN and Bosman FT: Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol. 178:48–52. 1996. View Article : Google Scholar
15.	Zhang Y: The ARF-B23 connection: implications for growth control and cancer treatment. Cell Cycle. 3:259–262. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Ulanet DB, Torbenson M, Dang CV, Casciola-Rosen L and Rosen A: Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci USA. 100:12361–12366. 2003. View Article : Google Scholar : PubMed/NCBI
17.	You BJ, Huang IJ, Liu WH, Hung YB, Chang JH and Yung BY: Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 360:683–690. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Gjerset RA: DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J Mol Histol. 37:239–251. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Li Z, Boone D and Hann SR: Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci USA. 105:18794–18799. 2008. View Article : Google Scholar
20.	Yung BY: c-Myc-mediated expression of nucleophosmin/B23 decreases during retinoic acid-induced differentiation of human leukemia HL-60 cells. FEBS Lett. 578:211–216. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Arabi A, Rustum C, Hallberg E and Wright AP: Accumulation of c-Myc and proteasomes at the nucleoli of cells containing elevated c-Myc protein levels. J Cell Sci. 116:1707–1717. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Grandori C, Gomez-Roman N, Felton-Edkins ZA, et al: c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol. 7:311–318. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Maiguel DA, Jones L, Chakravarty D, Yang C and Carrier F: Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol. 24:3703–3711. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Colombo E, Marine JC, Danovi D, Falini B and Pelicci PG: Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 4:529–533. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Lin CY, Liang YC and Yung BY: Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. Cell Signal. 18:2041–2048. 2006. View Article : Google Scholar : PubMed/NCBI